Video
Dr. Abou-Alfa on the Ongoing Impact and Role of Regorafenib in HCC
Author(s):
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.
Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the ongoing role and impact of regorafenib (Stivarga) in the paradigm of hepatocellular carcinoma (HCC) in an interview during the 2017 Chemotherapy Foundation Symposium.
Regorafenib, Abou-Alfa explains, is a unique agent that should not bee known as a "cousin" to sorafenib (Nexavar). In a study, regorafenib was compared with placebo in patients with HCC who progressed on sorafenib, which showed a 10.7-month improvement in survival.
Patients who progress on standard sorafenib will undoubtedly benefit from treatment with regorafenib, Abou-Alfa explains.
<<< View more from the 2017 Chemotherapy Foundation Symposium
